Guanfacine
Product Images NDC 50090-5991

7 FDA label images from A-s Medication Solutions · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Guanfacine (NDC 50090-5991). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure-1.jpg (Figure 1)

Figure-1.jpg (Figure 1)
A line graph showing plasma concentration of Guanfacine (ng/mL) over 24 hours. It compares Guanfacine Extended-Release Tablets, 1 mg QD, with Tenex, 1 mg QD. The x-axis represents time in hours, and the y-axis shows Guanfacine plasma concentration levels.*
FDA Label Image

Figure-2.jpg (Figure 2)

Figure-2.jpg (Figure 2)
A scatter plot chart illustrating the fold change and 90% confidence intervals in pharmacokinetic (PK) parameters Cmax and AUC due to various CYP3A4/5 inhibitors and inducers, as well as other drugs. The x-axis represents the change relative to reference from 0 to 5. Data points include ketoconazole, fluconazole, rifampin, efavirenz, oral methylphenidate, and lisdexamfetamine dimesylate, with separate values shown for Cmax and AUC.*
FDA Label Image

Figure-3.jpg (Figure 3)

Figure-3.jpg (Figure 3)
A forest plot chart illustrating the pharmacokinetic interaction of two drugs, Oral Methylphenidate and Lisdexamfetamine Dimesylate. It shows fold change and 90% confidence intervals for Cmax and AUC parameters relative to a reference, with values centered around 1.0 indicating no significant change.*
FDA Label Image

Figure-4.jpg (Figure 4)

Figure-4.jpg (Figure 4)
A Kaplan-Meier survival curve comparing time to treatment failure over days between placebo and SPD503 groups. The vertical axis represents the treatment failure rate percentage, and the horizontal axis represents time in days, up to 210 days. The placebo group shows a higher failure rate than the SPD503 group throughout the timeline.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
FDA Label Image

Label Image (Lbl500905991)

Label Image (Lbl500905991)
Label for Guanfacine Extended-Release 3 mg tablets by A-S Medication Solutions. The label indicates each tablet contains 3.42 mg of Guanfacine Hydrochloride equivalent to 3 mg Guanfacine. It includes storage instructions to keep at 68 to 77 degrees Fahrenheit, and the package contains 90 tablets. The label also shows the product NDC 50090-5991.*
FDA Label Image

Molecular-structure.jpg (Molecular Structure)

Molecular-structure.jpg (Molecular Structure)
Chemical structure of the active ingredient guanfacine hydrochloride, showing a dichlorinated phenyl ring attached to an amide and guanidine group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.